Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.

Neurocrine Biosciences has named Samir Siddhanti as its new Chief Business Officer, where he will oversee business development, corporate strategy, and alliance management to drive growth. Siddhanti has been with the company since 2017 and played a key role in expanding its pipeline, including leading the $2.9 billion acquisition of Soleno Therapeutics. His appointment signals Neurocrine's focus on leveraging both internal innovation and strategic partnerships to advance its pipeline and commercial portfolio. The company aims to continue developing new therapies for neurological and psychiatric disorders under his leadership.